EGFR and neoplasm: Considering recent studies that have shown clinical synergism between EGFR inhibitors and platinum-based chemotherapies (with the recent approval of the combination of osimertinib with carboplatin for advanced lung cancer),25–29,58 the coupling of an EGFR inhibitor to a platinum core in one molecule might offer a promising strategy to further enhance the tumor specificity and thus the therapeutic window of this drug combination.